US-based Uptake Medical has obtained CE mark approval for its InterVapor targeted ablation therapy for severe emphysema.
The InterVapor system uses heated water vapour to reduce bronchoscopic lung volume in patients with heterogeneous upper lobe emphysema.
Uptake Medical president and CEO King Nelson said: "Gaining CE Mark is a major milestone for our company, but more importantly, represents new hope for emphysema patients.
"We are eager to begin the commercial launch of InterVapor in Europe allowing more interventional pulmonologists to begin using the system in the months ahead."
The approval was based on results of the Step-Up study, which is a prospective, multi-center, multi-national and randomized-controlled trial that was completed in late2014.
The trial, which was conducted in 13 centers in Europe and Australia, has been designed to assess the safety and performance of the InterVapor system, in addition to the optimal medical standard therapy in improving lung performance and quality of life of patients with severe emphysema.
Step-Up trial results are expected to be presented in late September this year at the European Respiratory Society meeting.